Pura is a 322 amino acid sequence-speci®c singlestranded DNA-binding protein implicated in the control of both DNA replication and gene transcription Du et al., 1997; Haas et al., 1995; Kelm et al., 1997; Zambrano et al., 1997) . Structurally, the central region of Pura is composed of three 23 amino acid class I repeats interspersed with two 26 amino acid class II repeats . Evidently, the class I repeats of the central region of Pura are important for binding Pura to its single-stranded DNA target sequence, the purine-rich sequence element (GGN) n Johnson et al., 1995) . The class II repeats, characterized by acidic and leucine amino acid residues, are involved in the interaction between Pura and several transcriptional transactivators including HIV-1 Tat (Krachmarov et al., 1996) . The region from residues 261 through 275 contains a potential amphipathic ahelix with opposing basic and aromatic side chains. Within this amphipathic helix of Pura is a region of limited homology to large T-antigens of several polyomaviruses including SV40, JCV, and BKV (Ma et al., 1994) . Interestingly, the homology of Pura to Tantigen spans a region of T-antigen which is necessary for its interaction with the product of the retinoblastoma tumor suppressor gene, pRb (DeCaprio et al., 1988) . Accordingly, earlier studies have demonstrated that Pura has the ability to bind the hypophosphorylated form of pRb . Although the functional consequence of the interaction between these two proteins is yet undescribed, the selective interaction between Pura and the hypophosphorylated form of a protein involved in cell cycle progression suggests a potentially crucial role for Pura in the cell cycle.
Results from a large volume of studies have established that normal progression of cells from the G1 to S phase of the cell cycle is regulated in part by E2F-1 (for review see Nevins, 1992) . E2F-1 is a transcription factor which, by binding to the consensus E2F binding site, 5'-TTT(C/G)(C/G)CGC-3', present in the promoter regions of several S phase speci®c genes stimulates their transcription. During early G1 phase, the hypophosphorylated form of pRb binds to E2F-1 and prevents its transcriptional activity upon the S phase genes (for review see Weinberg, 1995) . The ability of Pura to bind to pRb prompted us to evaluate the transcriptional activity of its cellular partner, E2F-1, in cells overexpressing Pura and explore a possible interplay between Pura and E2F-1.
To this end, the human astrocytic cell line, U-87MG, was transfected with a DNA plasmid containing the dihydrofolate reductase gene (DHFR) promoter sequence fused to the reporter luciferase gene, alone or together with expression plasmids pCMV-E2F-1 and pCMV-Pura. Thirty-six hours post-transfection, protein extracts were prepared and examined for luciferase gene activity. In accord with earlier data, ectopic expression of E2F-1, in particular at a higher DNA concentration, caused a dramatic increase in the activity of DHFR promoter, most likely by associating with the E2F-1 consensus DNA sequence present in the DHFR promoter (Figure 1 , compare lane 1 with lane 3). Under similar conditions, expression of Pura in the transfected cells showed no stimulatory eect on the DHFR promoter (lanes 4 and 5). Surprisingly, overexpression of Pura and E2F-1 resulted in a drastic decrease in the ability of E2F-1 in activating the DHFR promoter (compare lane 3 with lanes 8 and 9). Since both E2F-1 and Pura are transcribed by an identical expression vector (pCDNA-3) the observed suppression of E2F-1 activity by Pura may not be attributed to the eect of Pura on the level of E2F-1 expression in the cells.
Eect of Pura on E2F-1 DNA binding activity
To examine the eect of Pura on the DNA binding activity of E2F-1, a synthetic DNA fragment representing the E2F-1 binding site from the DHFR gene promoter, and its mutant variant with no E2F-1 binding site was utilized as the probe in band shift assays. As illustrated in Figure 2a , bacterially produced GST-E2F-1 was able to bind the wild-type but not mutant DNA probe (compare lanes 3 and 8). This interaction cannot be due to the GST moiety of the GST-E2F-1 as GST alone had no ability to bind the probe (lanes 4 and 5). Next, a binding reaction was performed with GST-E2F-1 in the presence of the MBP-Pura fusion protein. As shown in Figure 2b , the addition of MBP-Pura fusion protein to the binding reaction caused a noticeable decrease in the intensity of the band corresponding to the GST-E2F-1:DNA protein complex (compare lane 3 with lanes 4 and 5). Figure 2b also shows that MBP-Pura has no ability to bind the double-stranded DNA sequence containing the E2F-1 binding site (lanes 6 and 7). Of note, as demonstrated in our previous study, MBP-Pura exhibits strong binding activity to the single-stranded GC-rich DNA (data not shown, also see . Under similar conditions, MBP showed no drastic eect on binding of GST-E2F-1 to its target DNA probe (lanes 8 and 9). Examination of the band shift data showed no evidence pointing to the formation of a larger nucleoprotein (E2F-1 : DNA : Pura) complex with slower electrophoretic mobility and/or the appearance of a new Pura : DNA complex. Thus, it seems likely that the observed inhibition of the assembly of the E2F-1 nucleoprotein complex by Pura is caused by direct communication of these two proteins which results in reduced E2F-1 DNA binding activity.
To further evaluate the eect of Pura on the association of E2F-1 with the E2F-1 DNA element, nuclear extracts from U-87MG cells were prepared and mixed with DHFR probe. In order to identify the E2F-1 : DNA nucleoprotein complex, the binding reaction was performed in the absence or presence of antibodies which recognize E2F-1 (KH95), pRb, and E2F4, or control normal sera (NS). As shown in Figure 3a , interaction of nuclear proteins from U-87MG cells with the E2F-1 DNA probe results in the formation of human astrocytic cells, U-87MG, were transfected with 4 mg of DHFR-luciferase construct (pMAE wt.Luc) (kindly provided by Dr Peggy Farnham, McArdle Laboratories, University of Wisconsin, Madison, WI, USA) alone or together with pCMV-E2F-1 and pCMV-Pura at low (2.5 mg) and high (10.0 mg) DNA concentrations by the Ca-phosphate precipitation method (Graham and van der Eb, 1973) . After 36 h, protein extracts were prepared and luciferase assays were performed according to the manufacturer's instructions (Promega, Madison, WI, USA) and were quantitated by the use of a Luminometer (Femptomaster FB12, Zylux Corporation). The concentration of DNA in the transfection mixture remained constant (24 mg) by the addition of pCMV vector DNA Figure 2 Binding of recombinant E2F-1 to the DHFR-E2F-1 binding site in the absence and presence of Pura. (a) Band shift assay was performed using 120 and 600 ng of puri®ed bacterially produced GST-E2F-1 (lanes 2 and 3, and lanes 7 and 8), or 120 and 600 ng of GST (lanes 4 and 5, and lanes 9 and 10) in the presence of wild-type DHFR-E2F-1 probe (5'-ATCTTTCGCGCGCTTTCTA-3') (lanes 1 ± 5) or its mutant variant (5'-ATCTTTCGTAGTCTTTCTA-3') (lanes 6 ± 10). The position of the E2F-1 complex is shown on the side. (b) Band shift assay was performed with DHFR-E2F-1 probe in the presence of 600 and 1000 ng of GST-E2F-1 (lanes 2 and 3, respectively), 1000 ng of GST-E2F-1 plus 250 and 500 ng of maltose binding protein fused to Pura (MBP-Pura) (lanes 4 and 5, respectively), 250 and 500 ng of MBP-Pura alone (lanes 6 and 7, respectively), and 1000 ng of GST-E2F-1 plus 250 and 500 ng of MBP (lanes 8 and 9) Regulation of E2F1 activity by Pura N Darbinian et al complexes with distinct electrophoretic mobilities ( Figure 3, lane 1) . The addition of the KH95, but not NS, to the binding mixture decreased the intensity of the bands corresponding to the DNA-protein complexes (compare lane 1 with lanes 2 and 5) suggesting the presence of E2F-1 in these complexes. Interestingly, the addition of anti-pRb antibody showed no detectable eect on the intensity of the complexes (lane 3). However, inclusion of anti-E2F4 antibody in the binding reaction modestly decreased the formation of the nucleoprotein complexes (compare lane 1 to lane 4). These observations suggest that the nucleoprotein complexes seen upon the addition of U-87MG extract to the DHFR DNA probe contain predominantly E2F-1. While a small fraction of the complexes may contain E2F4, no evidence for the participation of pRb in the complexes was detected.
To further demonstrate the presence of E2F-1 in the complexes, a competition experiment utilizing unlabeled oligonucleotide DNA containing the wild-type E2F-1 binding site or its mutant variants with no E2F-1 binding site was carried out. As shown in Figure 3b , while the addition of unlabeled wild-type E2F-1 competitor to the binding reaction severely decreased formation of the complexes (compare lane 1 to lanes 2 and 3), mutant competitor DNA with no binding site for E2F-1 had no signi®cant eect on the association of E2F-1 with the probe (Figure 3b , compare lane 1 to lanes 4 and 5).
Next, we examined the eect of Pura on the formation of the E2F-1 nucleoprotein complexes by utilizing nuclear extracts from control U-87MG cells or U-87MG cells transfected with plasmids expressing E2F-1, E2F-1 plus Pura, and E2F-1 plus Dp1 in bandshift assays. As illustrated in Figure 3c , the intensity of the complexes were slightly increased in the binding reaction containing nuclear extract from cells transfected with plasmid expressing E2F-1 (compare lane 1 to lane 3). Co-expression of Pura and E2F-1 caused a noticeable decrease in the intensity of the band related to the E2F complexes (compare lane 2 to lane 3). In contrast, co-production of E2F-1 and its partner, Dp1, modestly increased the assembly of E2F-1 with its target DNA sequence (compare lane 4 to lane 3). It should be mentioned that throughout these studies, we noticed that the observed eects were consistently more signi®cant in the slower migrating complex (upper band).
To examine the eect of exogenously added Pura on DNA binding activity of E2F-1 produced in cells, nuclear extracts from E2F-1 transfected U-87MG cells were mixed with MBP-Pura or MBP prior to incubation with the DNA probe. As shown in Figure  3d , inclusion of MBP-Pura, but not MBP, to the protein extract decreased the formation of the E2F-1 complexes (compare lane 1 with lanes 2 and 3, and lane 1 with lanes 4 and 5). Altogether these observations provide evidence that while Pura has no ability to bind to the DNA fragment containing the E2F-1 binding site, it can exhibit an inhibitory eect on the association of E2F-1 with its target DNA sequence.
Interaction between Pura and E2F-1
In order to examine the direct interaction between Pura and E2F-1, GST pull-down assays were performed. In the ®rst series of experiments, 35 S-methionine-labeled in vitro synthesized E2F-1 was mixed with GST or GSTPura beads according to the procedure described previously (Kundu et al., 1997) , and after elution, the bound proteins were analysed by SDS ± PAGE. As shown in Figure 4a (top), while no signal corresponding to E2F-1 was detected upon elution of the GST beads, a noticeable band which co-migrates with E2F-1 was observed in eluates from GST-Pura. In a reciprocal study, in vitro synthesized Pura was used in GST pull-down assays utilizing GST or GST-E2F-1 beads. As shown in Figure 4a (bottom), in vitro synthesized Pura was able to bind to GST-E2F-1, but not to GST beads. These results suggest that E2F-1 can directly bind to Pura and form an E2F-1 : Pura complex in vitro.
In the next series of experiments, we evaluated the in vivo association of Pura and E2F-1. Toward this end, nuclear protein extract was prepared from NIH3T3 cells that constitutively expresses high levels of human E2F-1 and utilized in immunoprecipitation/Western blot assay. Nuclear extracts were reacted with anti-E2F-1 antibody (KH95), normal sera (NS), or antiDp1 antibody, and the immunocomplexes were resolved by SDS ± PAGE followed by Western blot utilizing anti-Pura or anti-E2F-1 antibodies. As shown in Figure 4b (top), immunoprecipitation with KH95 was accompanied by precipitation of Pura (lane 1), indicating that E2F-1 and Pura are in complex in the nuclear protein extract. No band corresponding to Pura was detected in immunocomplexes obtained from normal sera or anti-Dp1 antibody (lanes 2 and 3, respectively). Similar results were obtained with nuclear extracts from human T lymphocytic cells, Jurkat (data not shown). As shown in Figure 4b (bottom), a substantial level of E2F-1 was detected in the complexes pulled-down by KH95, but not with NS (compare lane 1 with lane 2). As expected, anti-Dp1 antibody pulled-down a complex which also contained E2F-1, corroborating with earlier data indicating the ability of E2F-1 to bind to Dp1 (LaThangue, 1994) . These observations provide evidence that E2F-1 and Pura can form a Pura : E2F-1 complex, and that formation of this complex is independent from the DNA containing the E2F-1 binding site. In light of our functional data showing the ability of Pura to block E2F-1 DNA binding activity, one may conclude that by binding to E2F-1, Pura, may block the interaction of E2F-1 with its target DNA, and hence, decrease the transcriptional ability of this activator protein. It is also important to note that while Pura can associate with E2F-1, no evidence for its interaction with Dp1 was obtained. Whether association of Pura with Dp1 results in disruption of E2F-1 : Dp1 complex remains unclear at present.
Since association of two proteins with each other may alter their steady state levels, in the next series of experiments, the levels of E2F-1 and Pura were compared in cells expressing either protein alone or together. In this study U-87MG cells were transfected with low (2.5 mg) and high (10.0 mg) amounts of pCMV-Pura and/or pCMV-E2F-1 expression plasmids. The total amount of plasmid DNA in transfection mixtures was kept constant by adding control pCMV vector DNA. After 36 h, total protein extracts were prepared and analysed by Western blot utilizing anti-E2F-1 or anti-Pura antibodies. As shown in Figure 5a , in the presence of Pura, the level of E2F-1 was drastically increased as evidenced by the intensity of the band corresponding to E2F-1 in protein extracts from the cells transfected with 2.5 and 10.0 mg of pCMV-E2F-1 (compare lane 2 with lanes 6 and 7, and lane 3 with lanes 8 and 9). Again, as both Pura and E2F-1 are expressed by a similar expression vector, the observed increase in E2F-1 levels may not be due to the elevation of the E2F-1 gene expression by Pura. Thus, it is likely that by association with Pura and forming a Pura : E2F-1 complex (as shown in Figure 4 ), E2F-1 becomes more stable in the cells. Examination of the Pura level in the transfected cells, also showed an increase in the level of Pura in extracts from cells co-transfected with pCMV-Pura plus pCMV-E2F-1 in comparison to those seen in extracts from cells transfected with Pura alone (compare lane 5 with lane 9). These observations demonstrate that the interplay between E2F-1 and Pura, which brings stability to each one of these proteins by their association, may have an important role in the biological activity of E2F-1 in the control of S phase gene transcription.
In this communication, we demonstrate that Pura can interfere with the transcriptional activation of the S phase-speci®c gene, DHFR, by E2F-1. Evidently, Pura, by interacting with E2F-1 prevents its association with the E2F-1 elements located within the DHFR promoter. Earlier studies have shown that Pura associates with the hypophosphorylated form of pRb, a protein which complexes with E2F-1 in the G0 and early G1 phases of the cell cycle. Hyperphosphorylation of pRb in late G1 results in the release of the E2F-1 from pRb and allows E2F-1 to activate the genes necessary for progression through G1 and entry into S phase. Interestingly, Pura binds the same region of pRb as does E2F-1 suggesting that its association with pRb may liberate E2F-1. According to our data, Pura also binds to E2F-1 and inhibits its activity. The ability of Pura to bind E2F-1 and its cellular partner, pRb, suggests that Pura may play an important role in modulating the level of pRb : E2F-1 assembly, and therefore, E2F-1 activity in the cell cycle. Our future studies are aimed at critically evaluating the level of association of E2F-1 : Pura and pRb : Pura in relation to pRb : E2F-1 during various stages of the cell cycle, and determining whether overexpression of Pura deregulates the cell cycle event by disturbing the pRb : E2F-1 complex.
